Nanobiotix S.A. (NBTX) stock
NBTXNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as NNBXF
$27.45−1.09 (-3.82%)
Close on Nov 17, 2026Market cap $1.33BP/E –Yield –
Earnings
Nanobiotix's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Next report
–
Not yet scheduled
Revenue
–
EPS
–
Latest guidance
None
No outlook given in releases
Quarterly results
Revenue and earnings per share from each of Nanobiotix's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Source |
|---|---|---|---|---|---|
| Q4 FY2025ended Dec 31, 2025 | Mar 31, 2026after the close | – | – | – | Release |
| Q2 FY2025ended Jun 30, 2025 | Sep 30, 2025after the close | – | – | – | Release |
| Q4 FY2024ended Dec 31, 2024 | Apr 2, 2025after the close | – | – | – | Release |
| Q2 FY2024ended Jun 30, 2024 | Sep 18, 2024after the close | – | – | – | Release |
| Q4 FY2023ended Dec 31, 2023 | Apr 24, 2024after the close | – | – | – | Release |
| Q2 FY2023ended Jun 30, 2023 | Sep 26, 2023after the close | – | – | – | Release |
| Q4 FY2022ended Dec 31, 2022 | Mar 14, 2023after the close | – | – | – | Release |
| Q2 FY2022ended Jun 30, 2022 | Jul 13, 2022after the close | – | – | – | Release |
| Q4 FY2021ended Dec 31, 2021 | Mar 30, 2022after the close | – | – | – | Release |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Guidance
Nanobiotix has not given guidance in its releases
Many companies give their outlook only on the conference call or not at all. When Nanobiotix puts a forecast in an earnings release, it is listed here with the exact sentence.
Press releases
Releases Nanobiotix filed with the SEC as exhibits to Form 8-K or 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
See a number that looks wrong?